Filing Flows › Accelerant (ARX) › Takeover & LBO
Is Accelerant (ARX) a takeover target?
A leveraged buyout does not work for Accelerant on its latest figures: Accelerant is an insurer, so the buyout model is not run on it. Latest signal (2026-10-30): Agreed sale to its terms, the at $20.25 cash a share · pending.
Why a leveraged buyout does not fit
Accelerant is an insurer: its debt — deposits, policy reserves or property loans — is part of how it does business, so a model that lends against EBITDA does not describe what a buyer would pay. Deals for companies like it are priced on book value and earnings instead.
What a takeover could cost
Takeovers in its sector paid a median premium of 14.9% over the share price before the deal (the middle half 9.5% to 33.6%), according to the 17 merger proxies and tender-offer responses on EDGAR that state a premium.
Rumors and deal signals
- 2026-10-30 · deal · Agreed sale to its terms, the at $20.25 cash a share · pending
- 2026-10-30 · SC 13E3 · Going-private statement (Schedule 13E-3)
Accelerant's latest quarter
Accelerant, Q2 2026: revenue $357M (+63% year over year), operating margin 24.5%, net earnings $78.7M, operating cash flow −$68.6M. The chart follows the revenue to costs, profit and cash.
Questions
Is Accelerant being acquired?
The latest signal on file is from 2026-10-30: Agreed sale to its terms, the at $20.25 cash a share · pending. A headline is not a deal; Filing Flows lists the news, 8-K filings and 13D filings about a sale.
Could private equity buy Accelerant?
A leveraged buyout does not work for Accelerant on its latest figures: Accelerant is an insurer, so the buyout model is not run on it. Its debt is part of the business, so deals for companies like it are priced on book value and earnings, not on borrowing against EBITDA.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.